Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine?

Abstract:

IMPORTANCE OF THE FIELD:Migraine is an episodic, substantially inherited brain disorder affecting 15% of adults in Western Europe and North America, and is one of the commonest reasons for patients to see their physicians. While the World Health Organization considers that severe migraine can be as disabling as quadriplegia, unfortunately the condition remains undertreated. Until the 1990s, specific migraine therapies were limited to ergot derivatives. AREAS COVERED IN THIS REVIEW:The triptans, serotonin 5-HT(1B/1D) receptor agonists, revolutionized the acute management of migraine patients. However, although the triptans are generally effective and safe, not all patients can take them and many do not respond especially to oral therapies. Recently, progress has been made on the therapeutic front, particularly with new acute treatments. This review will focus on the therapeutic potential of ADX10059, a metabotropic glutamate receptor 5, negative allosteric modulator (mGluR5 NAM), in migraine. Data from a proof-of-concept study in episodic migraineurs demonstrated a significant improvement following acute treatment. A large European multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study is currently investigating the efficacy, safety and tolerability of the compound for migraine prevention. WHAT THE READER WILL GAIN:The reader will have the basic principles of migraine management and the potential for glutamate-targeted approaches. TAKE HOME MESSAGE:Targeting glutamatergic transmission in migraine may provide a novel preventive therapy that is effective and well-tolerated.

authors

Marin JC,Goadsby PJ

doi

10.1517/13543781003691832

subject

Has Abstract

pub_date

2010-04-01 00:00:00

pages

555-61

issue

4

eissn

1354-3784

issn

1744-7658

journal_volume

19

pub_type

杂志文章,评审
  • American Association for Cancer Research: Clinical trials of immunotherapeutics and immunologic monitoring. April 1-5, 2000, San Francisco, CA, USA.

    abstract::A major session at this annual gathering of the cancer researchers from around the globe dealt with the current state of immunotherapy for cancer. Immunotherapy is a form of cancer treatment that enhances its scientific promise and legitimacy with each passing year. As a result, this topic has become one of the most h...

    journal_title:Expert opinion on investigational drugs

    pub_type:

    doi:10.1517/13543784.9.6.1413

    authors: Salgaller ML

    更新日期:2000-06-01 00:00:00

  • Therapeutic developments in multiple sclerosis.

    abstract::Recently there have been considerable advances made in the treatment of multiple sclerosis. For the first time since its initial clinical description in the 1800s, there are now available several medications which unequivocally exert favourable clinical effects through the lowering of the biological activity of the hu...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.4.655

    authors: Goodin DS

    更新日期:2000-04-01 00:00:00

  • Beclabuvir for the treatment of hepatitis C.

    abstract:INTRODUCTION:About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). Currently, the most successful HCV infection antiviral therapies reduce the chance of progression towards the advanced phases of the hepatopathy (liver cirrhosis, hepatocellular carcinoma and death). Recently, however...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2015.1059820

    authors: Gentile I,Zappulo E,Buonomo AR,Maraolo AE,Borgia G

    更新日期:2015-01-01 00:00:00

  • Novel therapies for the prevention of malaria.

    abstract:BACKGROUND:Malaria continues to exact a huge toll on the health of residents of endemic countries. Thus, new approaches to prevention and treatment are needed. OBJECTIVE:To provide an update on novel therapies for the prevention of malaria. METHODS:Systematic MEDLINE search from 1956 to 2008 using the search term 'ma...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780802514039

    authors: Bojang KA

    更新日期:2008-12-01 00:00:00

  • Novel therapies in transplantation.

    abstract::Immunosuppressant drugs are crucial in order to protect transplanted kidney, heart or liver against the body's natural defence mechanisms. These drugs are used to prevent both acute rejection of the organ as well as chronic deterioration of the graft over longer periods of time. Currently used immunosuppressant drugs ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.14.3.295

    authors: Jorga A,Johnston A

    更新日期:2005-03-01 00:00:00

  • Investigational drugs for eating disorders.

    abstract::Anorexia nervosa (AN), bulimia nervosa (BN) and binge eating disorder (BED) each occur in about 0.5-1.5% of the population in westernised countries, and primarily affect women. At present, a variety of pharmacological treatments are used in addition to psychotherapy, with antidepressants being most the common. Current...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.4.427

    authors: Crow S

    更新日期:1997-04-01 00:00:00

  • Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease.

    abstract::Background: We aimed to estimate population-based trends in the prevalence of coexisting type 2 diabetes (T2D) and suspected nonalcoholic fatty liver disease (NAFLD) and pioglitazone use among U.S. adults.Research design and methods: We conducted a cross-sectional analysis of the National Health and Nutrition Examinat...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2020.1704731

    authors: Le P,Chaitoff A,Rothberg MB,McCullough A,Alkhouri N

    更新日期:2020-02-01 00:00:00

  • Antileukotrienes in clinical development for asthma.

    abstract::Asthma is a serious world health problem characterised by a chronic inflammatory disorder of the airways. Asthma attacks, or exacerbations, are episodic but airway inflammation is chronically present. Thus, this disorder requires long-term management. The goals of asthma management include prevention steps for long-te...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.1.49

    authors: Centanni S,Santus P

    更新日期:2002-01-01 00:00:00

  • The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure.

    abstract::In most countries the last two decades have seen a very substantial rise in the prevalence of heart failure, and in a majority of patients hypertension is both an antecedent condition and a contributing cause. Heart failure is also a major cause of hospital admissions; its amelioration and, as far as possible, prevent...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.12.1963

    authors: Funder JW

    更新日期:2003-12-01 00:00:00

  • Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases.

    abstract::Prinomastat (formerly AG3340, Agouron Pharmaceuticals, Inc.) is a potent, selective oral inhibitor of matrix metalloproteinase-2, -9, -13 and -14. This peculiar selectivity should represent an advantage for prinomastat in terms of efficacy/tolerability. The drug has been shown to inhibit tumour growth and angiogenesis...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.9.2159

    authors: Scatena R

    更新日期:2000-09-01 00:00:00

  • Recent and ongoing clinical trials for treating colorectal cancer.

    abstract::Colorectal cancer is one of the most common cancers worldwide. Through well-designed clinical trials, advances have been made in the treatment of localised and advanced colorectal cancer. It has been established that 6 months of 5-fluorouracil-based chemotherapy will improve overall survival in patients with stage III...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.6.871

    authors: Mulcahy MF,Benson AB 3rd

    更新日期:2002-06-01 00:00:00

  • Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis.

    abstract:INTRODUCTION:Rheumatoid arthritis (RA) is a chronic inflammatory auto-immune disease that can lead to permanent disability and deformity. Despite current treatment modalities, many patients are still unable to reach remission. Interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors are novel agents designed to s...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2020.1752660

    authors: Wiese MD,Manning-Bennett AT,Abuhelwa AY

    更新日期:2020-05-01 00:00:00

  • Therapeutic targets and early stage clinical trials for pulmonary fibrosis.

    abstract:INTRODUCTION:Idiopathic pulmonary fibrosis (IPF) is an age-associated, progressive, and irreversible fatal interstitial lung disease. Although many drugs have failed in clinical trials, these failures improved the understanding of the pathogenesis of IPF. Currently, there are two drugs approved for IPF that slow the pr...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2019.1554054

    authors: Sato S,Yanagihara T,Kolb MRJ

    更新日期:2019-01-01 00:00:00

  • Endothelin receptor antagonists in cardiology clinical trials.

    abstract::Endothelin-1 (ET-1) is enhanced and has been demonstrated to be a prognostic marker in patients with advanced stages of heart failure, acute ischaemic syndromes, myocardial infarction and pulmonary hypertension. Activation of the endothelin (ET) system is associated with adverse haemodynamic consequences in patients w...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.3.431

    authors: Neunteufl T,Berger R,Pacher R

    更新日期:2002-03-01 00:00:00

  • Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor.

    abstract:BACKGROUND:Histone deacetylases (HDACs), which target histones as well as non-histone proteins as substrates, have the potential to regulate aberrant gene expression and restore normal growth control in malignancies. OBJECTIVE:This review provides an updated summary of preclinical and clinical experience with the oral...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.17.8.1247

    authors: Le Tourneau C,Siu LL

    更新日期:2008-08-01 00:00:00

  • Tetomilast: new promise for phosphodiesterase-4 inhibitors?

    abstract:INTRODUCTION:Tetomilast is a novel thiazole phosphodiesterase-4 (PDE-4) inhibitor, which may prove useful in both the treatment of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD). Here, the authors review the pharmacology of the drug, and offer critical review of the available data for...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2012.732065

    authors: Bickston SJ,Snider KR,Kappus MR

    更新日期:2012-12-01 00:00:00

  • Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective.

    abstract:IMPORTANCE OF THE FIELD:Curcumin has been investigated in preclinical and translational stroke models because of its pleiotropic 'neuroprotective' activities. Since curcumin has poor blood-brain barrier (BBB) penetration following acute administration, creative medicinal chemistry has been used to modify the parent cur...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2011.542410

    authors: Lapchak PA

    更新日期:2011-01-01 00:00:00

  • Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol).

    abstract:BACKGROUND:Today, propofol or 2,6-diisopropylphenol is the anesthetic mainly used for monitored anesthetic care sedation and during intravenous anesthesia. The formulation, a lipid macroemulsion, shows several disadvantages. Therefore, during the past years considerable scientific effort has been undertaken to find eit...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780903193063

    authors: Fechner J,Ihmsen H,Jeleazcov C,Schüttler J

    更新日期:2009-10-01 00:00:00

  • Mometasone furoate nasal spray for the treatment of asthma.

    abstract:INTRODUCTION:Asthma is a common respiratory disease characterized by airway inflammation, bronchoconstriction and airway hyperresponsiveness and symptoms such as coughing, wheezing, shortness of breath and chest tightness. Allergic rhinitis is a common comorbidity in asthma and glucocorticoids are the key stone in the ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2016.1192124

    authors: Meteran H,Backer V

    更新日期:2016-08-01 00:00:00

  • Antisense approach for the treatment of cytomegalovirus infection.

    abstract::Human cytomegalovirus (HCMV) is the most common viral opportunistic infection in patients suffering with acquired immunodeficiency virus (AIDS). HCMV is a systemic infection that may infect several sites in the body, including the retina, gastrointestinal tract, lungs, liver, and central nervous system. Retinitis is t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.9.1157

    authors: Temsamani J,Pari GS,Guinot P

    更新日期:1997-09-01 00:00:00

  • New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation.

    abstract:IMPORTANCE OF THE FIELD:Treatments of pulmonary arterial hypertension (PAH) that have so far proven efficacious are all based on the restoration of endothelium control of pulmonary vascular tone and structure, by administration of prostacyclins, endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Howeve...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543781003727099

    authors: Dewachter L,Dewachter C,Naeije R

    更新日期:2010-04-01 00:00:00

  • The role of telavancin in the treatment of MRSA infections in hospital.

    abstract:BACKGROUND:Serious infections caused by Gram-positive bacteria, particularly multi-drug resistant, are an important cause of morbidity and mortality in patients admitted to intensive care units. Thus, new antibiotics covering these pathogens are urgently needed. OBJECTIVE:To review characteristics of telavancin, a nov...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780902845630

    authors: Bassetti M,Mikulska M,Righi E,Nicolini L,Viscoli C

    更新日期:2009-04-01 00:00:00

  • Current and investigational drugs for the treatment of diabetic retinopathy.

    abstract:INTRODUCTION:Diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) are the two complications of diabetes that cause visual loss and blindness. Laser photo-coagulation in the past was used to prevent progression of disease to these advanced stages. Advances in pathophysiologic understanding of DME an...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2016.1201062

    authors: Tolentino MS,Tolentino AJ,Tolentino MJ

    更新日期:2016-09-01 00:00:00

  • Treatment of neurodegenerative diseases with neural cell transplantation.

    abstract::Neural cell transplantation is an emerging therapy that may provide an effective treatment for neurodegenerative disorders. The most extensive work with neural transplants has been carried out for Parkinson's and Huntington's diseases. However, intensive efforts are also being made for the treatment of other neurologi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.4.527

    authors: Dinsmore JH

    更新日期:1998-04-01 00:00:00

  • Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.

    abstract::Inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) has an established role in the treatment of advanced non-small cell lung cancer. The first-generation EGFR inhibitors erlotinib and gefitinib have been approved for treatment in the second- and third-line setting. Second-generation ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780902762843

    authors: Mukherji D,Spicer J

    更新日期:2009-03-01 00:00:00

  • COX-2 inhibitors as adjunctive therapy in schizophrenia.

    abstract::Cyclooxygenase-2 (COX-2) is constitutively expressed in the central nervous system, and is thought to have an important functional role therein. COX-2 interacts with neurotransmitters such as acetylcholine, 5-hydroxytryptamine and glutamate but is also involved in the regulation of the central nervous system immune sy...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.13.8.1033

    authors: Müller N,Strassnig M,Schwarz MJ,Ulmschneider M,Riedel M

    更新日期:2004-08-01 00:00:00

  • Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial.

    abstract:BACKGROUND:Age-related macular degeneration is the leading cause of blindness among elderly individuals in industrialized countries. New drugs and advanced concepts for the treatment of dry AMD (dAMD) are needed. A new approach is the application of intravenous infusions of prostaglandin E1. OBJECTIVE:The aim of this ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1517/13543784.2013.794782

    authors: Augustin AJ,Diehm C,Grieger F,Bentz J

    更新日期:2013-07-01 00:00:00

  • Sirukumab : a novel therapy for lupus nephritis?

    abstract:INTRODUCTION:Lupus nephritis (LN) is a significant contributor to morbidity and mortality in systemic lupus erythematosus (SLE). Current therapies for LN are limited by significant toxicities and high rates of relapse. A clear and present need exists for the development of effective, targeted and well-tolerated treatme...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.950837

    authors: Thanarajasingam U,Niewold TB

    更新日期:2014-10-01 00:00:00

  • Pharmacological methods to overcome IFN-beta antibody formation in the treatment of multiple sclerosis.

    abstract::Diminished efficacy in terms of clinical relapses and lesion load on magnetic resonance images for patients developing neutralising antibodies (NAbs) to recombinant IFN-beta may be found in multiple sclerosis. NAbs become detectable over the first few years of therapy, disappearing during the treatment course in some ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.7.1153

    authors: Bagnato F,Pozzilli C

    更新日期:2003-07-01 00:00:00

  • Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy.

    abstract::PDE3 cyclic nucleotide phosphodiesterases are important in cyclic AMP (cAMP) and possibly cyclic GMP-mediated signalling in cardiac and vascular smooth muscle myocytes. Drugs that inhibit these enzymes have inotropic and vasodilatory actions that have proven useful in the short-term treatment of contractile failure an...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.11.1529

    authors: Movsesian MA,Alharethi R

    更新日期:2002-11-01 00:00:00